BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2636 related articles for article (PubMed ID: 15657900)

  • 1. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
    Menendez JA; Vellon L; Colomer R; Lupu R
    Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
    Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells.
    Menendez JA; Lupu R
    Int J Mol Med; 2005 Jan; 15(1):33-40. PubMed ID: 15583825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA; Vellon L; Lupu R
    Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis.
    Menendez JA; Ropero S; Mehmi I; Atlas E; Colomer R; Lupu R
    Int J Oncol; 2004 Jun; 24(6):1369-83. PubMed ID: 15138577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of tumor-associated fatty acid synthase activity enhances vinorelbine (Navelbine)-induced cytotoxicity and apoptotic cell death in human breast cancer cells.
    Menendez JA; Colomer R; Lupu R
    Oncol Rep; 2004 Aug; 12(2):411-22. PubMed ID: 15254710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel CYR61-triggered 'CYR61-alphavbeta3 integrin loop' regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway.
    Menendez JA; Vellon L; Mehmi I; Teng PK; Griggs DW; Lupu R
    Oncogene; 2005 Jan; 24(5):761-79. PubMed ID: 15592521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asiatic acid, a triterpene, induces apoptosis and cell cycle arrest through activation of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways in human breast cancer cells.
    Hsu YL; Kuo PL; Lin LT; Lin CC
    J Pharmacol Exp Ther; 2005 Apr; 313(1):333-44. PubMed ID: 15626723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
    Menendez JA; Vellon L; Lupu R
    Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of ERK 1/2 and p38 MAP-kinase pathways in taxol-induced apoptosis in human ovarian carcinoma cells.
    Seidman R; Gitelman I; Sagi O; Horwitz SB; Wolfson M
    Exp Cell Res; 2001 Aug; 268(1):84-92. PubMed ID: 11461121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53.
    Bacus SS; Gudkov AV; Lowe M; Lyass L; Yung Y; Komarov AP; Keyomarsi K; Yarden Y; Seger R
    Oncogene; 2001 Jan; 20(2):147-55. PubMed ID: 11313944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival.
    Wu W; Pew T; Zou M; Pang D; Conzen SD
    J Biol Chem; 2005 Feb; 280(6):4117-24. PubMed ID: 15590693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer.
    Shi YY; Small GW; Orlowski RZ
    Breast Cancer Res Treat; 2006 Nov; 100(1):33-47. PubMed ID: 16807678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
    Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells.
    Menendez JA; Oza BP; Atlas E; Verma VA; Mehmi I; Lupu R
    Oncogene; 2004 Jun; 23(28):4945-58. PubMed ID: 15094777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition.
    MacKeigan JP; Taxman DJ; Hunter D; Earp HS; Graves LM; Ting JP
    Clin Cancer Res; 2002 Jul; 8(7):2091-9. PubMed ID: 12114408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation.
    Menendez JA; Mehmi I; Verma VA; Teng PK; Lupu R
    Mol Carcinog; 2004 Nov; 41(3):164-78. PubMed ID: 15390078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulation of cyclin-dependent kinase-4 and MAPK through estrogen receptor mediated cell cycle arrest in human breast cancer induced by gold nanoparticle tagged toxin protein NKCT1.
    Bhowmik T; Gomes A
    Chem Biol Interact; 2017 Apr; 268():119-128. PubMed ID: 28322778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
    Menendez JA; Oza BP; Colomer R; Lupu R
    Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 132.